info@seagull-health.com
SeagullHealth
search
Zanidatamab(Ziihera)
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
Ziihera(Zanidatamab) Instructions:Uses,Dosage, Side Effects
ZIIHERA, with the generic name zanidatamab-hriti, is a humanized, bispecific IgG1 antibody targeting the HER2 protein. It is produced using recombinant DNA technology in Chinese hamster ovary cells. The product is supplied as a sterile, white lyophilized powder in single-dose vials containing 300 mg of the active substance, alongside inactive ingredients such as polysorbate 20, sucrose, and sodium succinate buffer. It requires reconstitution and dilution before administration as an intravenous infusion.
ZIIHERA is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test, following prior gemcitabine-containing chemotherapy.
Recommended dose: 20 mg/kg administered as an intravenous infusion once every 2 weeks.
- Core products
- Antitumor drugs
- General drug
- Antiviral drugs
- Biological agents
- mailbox：info@lucius.la
